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Eleven deaths (0.2%) and 1,259 injuries (27.2%) were also documented. In preparation for this analysis response to the article by Frank and coworkers, we conducted a search of the MAUDE database (January 1, 2010, to September 30, 2010) for the CONTOUR ® TS meter (Bayer Healthcare, Tarrytown, NY) and found 3 "injury" and 36 "malfunction" reports. Recognizing that approximately 6.2 billion glucose meter measurements are conducted each year in the United States, it is not yet clear if the small proportion of serious adverse events in the MAUDE database indicates the success of current regulatory standards, or if more stringent standards could prevent or reduce the number of adverse outcomes reported overall or in patient subgroups.
What criteria need to be met to ensure sufficiently accurate glucose meter performance for patients? Both CLSI and ISO continue to develop and refine their guidelines for assessing glucose meter performance; the CLSI Point-of-Care Testing (POCT) revision, POCT12-A3, is in preparation as of 2010. In ISO 15197, the minimum acceptable performance expectations for glucose meter performance are that 95% of the individual glucose results shall fall within ±15 mg/dl (0.83 mmol/liter) at low glucose concentrations (<75 mg/dl, <4.2 mmol/liter) and within ±20% when glucose concentrations are higher. The performance goals used to evaluate glucose meters need to be sufficiently narrow to enable consistent medical decisions. At this time, there is a single standard applied to glucose meters used on all patients. As Frank and colleagues have shown in their evaluation, when ambulatory adults are assessed, devices such as the CONTOUR TS have performance that clearly surpasses the ±20% criteria. The percent concordance of glucose results for capillary blood and the Yellow Springs Instrument Co. (Yellow Springs, OH) plasma reference method was between 97.9 to 98.6% at the ±20% expectation and 91.7 to 93.3% at a ±15% expectation. When venous blood was analyzed, the percent concordance increased to 99.8% at a ±20% expectation and 97.9% at a ±15% expectation. The patient population examined in this evaluation represents an ambulatory diabetic community. Relative to the current analytical goals outlined in the error grid figures, we note the excellent analytical performance with the CONTOUR TS and that this performance has also been observed with many other commercial glucose meters when evaluation is performed on ambulatory patients without anemia.
When regulatory performance criteria are met, should we have confidence to use a medical device with all patients? The report by Frank and colleagues fulfils regulatory performance expectations for use of the CONTOUR TS; however, it did not evaluate performance over the full range of glycemia and hematocrits observed in hospitalized and critical care adults, pediatrics, and neonates. These heterogeneous patient groups require stringent glucose monitoring, and the composition of their blood is more variable than in healthier populations. Whole blood glucose monitoring devices are often prone to matrix effects that can modify analytical performance, and the extent of interference may depend on glucose concentration. 7, 8 To achieve performance targets with these heterogeneous hospitalized patients implies that the methods need to be precise and relatively free from matrix influences. In the future, it is possible that regulatory agencies could require assessment of matrix effects on whole blood glucose testing to ensure 
